Skip to main content
    S

    Silexion Therapeutics Corp (SLXN)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $1.65
    -0.11 (-6.25%)

    Market Cap: $1.14M

    Last updated: Nov 17, 2026 at 4:11 PM ET

    Silexion Therapeutics Corp (SLXN) Statistics

    Updated Nov 17, 2026. Figures from company filings and market prices; estimates from consensus analysts.

    Silexion Therapeutics (SLXN) has a market cap of $1.14M. It kept -24052.73% of revenue as net income over the last 12 months. It holds $4.76M more cash than debt, 416.38% of its market cap.

    Total Valuation

    Market Cap$1.14M
    Latest price (Nov 17, 2026)$1.65

    Key Dates

    Last Earnings DateNov 12, 2026
    Fiscal Year EndDecember

    Share Statistics

    The share count fell 73.10% in the quarter ended Sep 30, 2026.

    Shares Outstanding184.93K
    Shares Change (QoQ)-73.10%

    Valuation Ratios

    Sales and book value multiples are 5.5x and 0.1x.

    P/S Ratio5.5x
    P/B Ratio0.1x

    Price Statistics

    The stock is down 99.76% over 52 weeks and trades 69.61% below its 50-day average.

    Beta (1Y)3.26
    52-Week Change-99.76%
    1-Month Change-55.07%
    3-Month Change-83.36%
    6-Month Change-97.44%
    Total Return (1Y)-99.76%
    Return vs SPY (1Y)-111.29%
    Max Drawdown (1Y)-99.78%
    Max Drawdown (3Y)-100.00%
    Sharpe Ratio (1Y)-3.25
    Correlation with SPY (1Y)0.24
    50-Day Average$5.43
    200-Day Average$130.59
    52-Week Range$1.74 to $777.12
    RSI (14 Days)27.0
    Average Volume (20 Days)647.79K

    Price chart

    Financial Position

    Current assets cover 1.66x current liabilities, and total debt is 0.00x shareholder equity.

    Current Ratio1.66x
    Quick Ratio1.66x
    Debt / Equity0.00x

    Returns and Efficiency

    Return on equity is -445.72% and return on assets is -193.77% over the last 12 months.

    Return on Equity (ROE)-445.72%
    Return on Assets (ROA)-193.77%
    Return on Capital Employed (ROCE)-418.12%
    Asset Turnover0.01x

    Scores

    SLXN has an Altman Z-Score of -19.00, in the distress zone below 1.81, and a Piotroski F-Score of 3 of 9, in the average band of 3 to 7.

    Altman Z-Score-19.00
    Altman Z ZoneDistress
    Piotroski F-Score3 of 9
    Piotroski StrengthAverage

    Income Statement

    Revenue of $55.00K over the last 12 months is up 83.33% from the 12 months before.

    Revenue$55.00K
    Revenue Growth (YoY)+83.33%
    Gross Profit$55.00K
    Operating Income-$13.43M
    Pretax Income-$13.23M
    Net Income-$13.23M
    EBITDA-$13.14M
    EBIT-$13.15M
    Reported EPS (TTM)-$41.48

    Trailing 12 months through Sep 30, 2026.

    Full financial statements

    Balance Sheet

    Shareholder equity funds 43.48% of the $6.83M in total assets.

    Cash and Equivalents$4.76M
    Total Debt$0
    Net Cash$4.76M
    Net Cash Per Share$25.74
    Working Capital$2.43M
    Shareholder Equity$2.97M
    Book Value Per Share$16.05
    Total Assets$6.83M
    Total Liabilities$3.86M

    Balance sheet as of Sep 30, 2026.

    Full balance sheet

    Cash Flow

    Operating Cash Flow-$11.70M
    FCF Per Share-$18.52
    Depreciation and Amortization$10.00K
    Share Repurchases$490.00K

    Trailing 12 months through Sep 30, 2026.

    Full cash flow statement

    Margins

    The operating margin is -24425.45%.

    Gross Margin100.00%
    Operating Margin-24425.45%
    Pretax Margin-24052.73%
    Net Margin-24052.73%
    EBITDA Margin-23898.18%
    EBIT Margin-23916.36%

    Dividends and Yields

    SLXN does not pay a dividend.

    Buyback Yield-986.14%
    Shareholder Yield-986.14%

    Stock Splits

    The last split was a 1-for-24 reverse split on Nov 11, 2026.

    Last Split DateNov 11, 2026
    Split TypeReverse split
    Split Ratio1:24

    Peer Position

    Against 4 similar companies, SLXN has the 3rd highest P/S.

    P/S Ratio5.5x vs 8.7x median
    Revenue Growth (Trailing 4 Quarters, YoY)+83.33% vs +112.34% median

    Competitors compared

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    Frequently Asked Questions About SLXN

    What is SLXN's market cap?

    Silexion Therapeutics has a market cap of $1.14M.

    How many shares of SLXN are outstanding?

    Silexion Therapeutics has 184.93K shares outstanding.

    Does SLXN pay a dividend?

    No. Silexion Therapeutics does not pay a dividend.

    How much debt does SLXN have?

    Silexion Therapeutics has $0 of total debt and $4.76M of cash and equivalents, a net cash position of $4.76M.